Advances in Emerging Therapies 2006

Lees, Kennedy R.; Dawson, Jesse

doi:10.1161/01.str.0000254718.22566.90

Cited by 4 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The influential ESPRIT antiplatelet trial has impacted recent major guidelines for secondary stroke prevention, strengthening the recommendation for use of extended-release dipyridamole/aspirin over aspirin alone (see below). Editorial commentaries by stroke experts [21][22][23][24] support the interpretation of the ESPRIT Study Group: "The ESPRIT results, combined with the results of the previous trials, provide sufficient evidence to prefer the combination regimen of aspirin plus All results based on intention-to-treat analysis unless otherwise specified.…”

Section: Review Articlementioning

confidence: 99%

What’s new in stroke? The top 10 studies of 2006–2008. Part II

Hart¹

2008

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Ten studies from 2006-2008 that have importantly influenced clinical management of stroke and threatened stroke are presented. In Part I, four randomized clinical trials testing antithrombotic agents for secondary prevention of noncardioembolic ischemic stroke are analyzed. Clopidogrel and extended-release dipyridamole/low-dose aspirin in patients with recent ischemic stroke are shown to be about equal for reducing recurrent stroke in the giant international PRoFESS trial. Combination antiplatelet therapy with clopidogrel plus aspirin is not better than either alone for prevention of vascular events and causes more serious bleeding based on the CHARISMA trial. Extended-release dipyridamole/low-dose aspirin is better than low-dose aspirin alone for secondary stroke prevention from ESPRIT. Based on the second component of ESPRIT, aspirin is as good as anticoagulation after noncardioembolic brain ischemia. These trials, together involving 39,742 participants, have influenced 2008 European and North American guidelines for secondary prevention of noncardioembolic stroke, and these guideline recommendations are reviewed.

show abstract

Section: Review Articlementioning

confidence: 99%

What’s new in stroke? The top 10 studies of 2006–2008. Part II

Hart¹

2008

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…This is an ongoing Phase I clinical trial to assess the safety and exequibility of intra-arterial autologous BM-MNC transplantation during the acute phase in adult patients with ischemic stroke (<1week from symptom onset, NIHSS score [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] in the MCA territory.…”

Section: Bone Marrow Cell Transplantation In Strokementioning

confidence: 99%

“…However, to date, none of the drugs tested, although effective in animal models, have been effective in humans [4] and new strategies must be developed in an attempt to avoid neuronal death and/or restore lost brain function following a stroke.…”

mentioning

confidence: 99%

Potential Roles of Bone Marrow Stem Cells in Stroke Therapy

et al. 2007

View full text Add to dashboard Cite

There is a need for improved therapies, in terms of utility and effectiveness, for stroke patients; however, over the years, numerous clinical trials of potential drugs have failed to demonstrate positive results. The emerging field of stem cell research has raised several hopes of a therapy for neurological diseases, including stroke. This review discusses the recent clinical trials and pilot studies using stem cells in stroke patients and highlights key issues that must be addressed to improve the chances of successfully developing a new strategy for stroke patients using adult stem cells.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Much interest has focused on the prevention and treatment of neurodegenerative diseases and stroke, 1,2 but challenges relating to the complexity of the central nervous system (CNS) and neuronal death have been difficult to overcome. [3][4][5][6][7][8][9] One focus of the search for effective new drugs has been on complementary and alternative medicines. Medicinal plants have the great advantage that they have followed an indirect clinical trial during centuries of traditional use and usually many of the adverse effects and toxicities are known.…”

Section: Introductionmentioning

confidence: 99%

Neuroprotective effects of Lepidium meyenii (Maca)

Pino‐Figueroa

Nguyen

Maher

2010

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The neuroprotective activity of the plant Lepidium meyenii (Maca) was studied in two experimental models: in vitro and in vivo. Crayfish neurons were pretreated with vehicle or the pentane extract from Maca, subjected to H(2)O(2), and their viability determined microscopically and chemically. A significant concentration-neuroprotective effect relationship was demonstrated. The pentane extract was then administered intravenously to rats prior to and following middle cerebral artery occlusion. While infarct volumes were decreased for the lower dose, higher doses increased infarct volumes compared to controls. These results suggest a potential application of Maca as a neuroprotectant.

show abstract

Advances in Emerging Therapies 2006

Cited by 4 publications

References 17 publications

What’s new in stroke? The top 10 studies of 2006–2008. Part II

What’s new in stroke? The top 10 studies of 2006–2008. Part II

Potential Roles of Bone Marrow Stem Cells in Stroke Therapy

Neuroprotective effects of Lepidium meyenii (Maca)

Contact Info

Product

Resources

About